Following last week's announcement that Thermo Fisher plans to buy Life Technologies for $13.6 billion, Ion Torrent customers are taking a wait-and-see approach, although many are optimistic that the acquisition could be a boon to Ion Torrent development and to the next-gen seque
Fox Chase Cancer Center has contracted genomics interpretation company N-of-One to interpret and curate results from its new targeted sequencing-based test, CancerCode45, creating reports for ordering physicians that link genomic findings with potential targeted therapies.
NEW YORK (GenomeWeb News) – Molecular data interpretation firm N-of-One today announced a deal with Fox Chase Cancer Center to provide interpretation and treatment strategy services for genome sequencing and testing.
The Fox Chase Cancer Center has begun offering targeted sequencing to inform cancer treatment using an adaptation of Life Technologies' Ion Torrent AmpliSeq Cancer Panel via its CLIA-certified laboratory.
NEW YORK (GenomeWeb News) – If genetic tests that predict individual cancer risk are not reimbursed by health insurers, some people who have received referrals for those tests may opt not to take them, according to a new study from Fox Chase Cancer Center.